Nanobiotix Shares Shatter a Twelve-Year Record High

Breaking Past 31 Euros

Today, by crossing the 31 euros mark, Nanobiotix has erased a record that stood for over twelve years. The previous high, set at 30.28 euros on February 13, 2014, had long been an unattainable ceiling for the medtech company specializing in nanomedicine. The stock is now significantly above its 50-day moving average, which is at 19.89 euros, indicating a substantial gap between the current price and its medium-term trend. This disconnection is accompanied by an RSI of 82, well above the usual overbought threshold of 70, suggesting that buying pressure has been particularly intense in recent sessions. The stock has also crossed the upper Bollinger band, set at 27.77 euros, confirming the magnitude of the ongoing bullish movement. The previous resistance, identified at 28.90 euros — which was the closing price the day before — has been clearly surpassed. With no historical technical reference above 31 euros, the stock is now in uncharted territory.

Remarkable Stock Performance Across All Time Frames

Nanobiotix's stock performance stands out in its magnitude across all time scales. The stock has risen 67% over three months and nearly 873% over a year, a trajectory that ranks it among the most significant gains on the Parisian market. This path is all the more notable as the stock's beta, measured at -0.07, indicates an almost complete lack of correlation with general market fluctuations, meaning that Nanobiotix's recent developments are driven by company-specific factors rather than the overall market trend. Listed in Paris and also on the Nasdaq, the company develops nanoparticle-based technology aimed at enhancing the effectiveness of anticancer radiotherapy. The monthly volatility of the stock, measured at 18.85%, remains high, reflecting the magnitude of daily fluctuations to which investors are exposed. No immediate financial calendar events have been identified for the company at this stage.